Neurocrine Biosciences, Inc.

The provided transcript of Neurocrine Biosciences' Q1 2026 earnings call does not mention any current or planned fundraising activities through debt or equity. Key points regarding financial matters include: - No discussion of new debt or equity fundraising during the call. - Focus on strong operating income (around $200 million GAAP and non-GAAP). - Capital allocation priorities emphasize driving revenue growth, advancing the pipeline, and strategic business development. - Pending acquisition of Soleno Therapeutics expected to close in Q2 2026, with no financial guidance yet on the transaction. - No commentary on raising new capital; emphasis on durable cash flows funding ongoing R&D and business development. In summary, there is no indication of current or future fundraising through debt or equity discussed during this earnings call.

- No specific current or future capital expenditures (capex) or capital investment details were explicitly mentioned during the call. - The company is focused on strategic business development aligned with its capital allocation priorities: - Drive revenue growth - Advance the pipeline - Invest in business development - Pending acquisition of Soleno Therapeutics and its product VYKAT XR expected to close in Q2, representing a strategic expansion to strengthen long-term growth. - Continuing investment in R&D with plans to initiate 6 new Phase I and 4 new Phase II programs in 2026. - Operating expenses related to commercial expansion will be more apparent starting in Q2 2026. - Overall, financial strength and cash flow generation support ongoing investments in innovation and strategic opportunities.

- INGREZZA reaffirmed 2026 sales guidance of $2.7 billion to $2.8 billion, expecting strong growth driven by double-digit volume increase and record new patient additions. - CRENESSITY sales are annualizing at over $600 million, with steady new patient starts, strong persistency, broad prescriber adoption, and favorable reimbursement, positioning it as a potential blockbuster. - Expanded sales force and ongoing commercial investments are expected to further accelerate CRENESSITY adoption and depth of prescribing. - The pending acquisition of Soleno Therapeutics and addition of VYKAT XR will strengthen the commercial portfolio and contribute to growth. - Pipeline advancements, including key data readouts in 2027 for several programs, support long-term growth potential. - Overall, Neurocrine expects record net product sales in 2026 and sustained revenue growth driven by commercial execution and pipeline progress.

- Neurocrine Biosciences expects record net product sales in 2026 driven by INGREZZA, CRENESSITY (annualizing over $600 million), and the pending addition of VYKAT XR. - INGREZZA guidance is reaffirmed at $2.7 billion to $2.8 billion for the year. - Continued momentum in commercial portfolio and pipeline progress supports growth. - No specific forward guidance on earnings, operating earnings, or EPS was provided in the excerpts. - Tax rate expected between 22%-24% non-GAAP effective for 2026 and low 20s percent longer term, which impacts net profitability. - Management highlighted steady and consistent new patient starts and reimbursements, supporting revenue growth. - Investments in R&D with 6 Phase I and 4 Phase II programs planned in 2026 position the company for future pipeline-driven growth beyond 2026.

The transcript does not specifically mention current or expected orderbook or pending orders in quantitative terms. However, relevant commercial and sales information includes: - CRENESSITY new patient starts remain steady and consistent with positive momentum. - Persistence and compliance rates for CRENESSITY are strong and consistent through about 5 quarters of launch. - Expanded field sales team for CRENESSITY expected to increase prescriber engagement and new patient starts. - INGREZZA showed strong underlying demand and managed seasonality well, with guidance reaffirmed at $2.7B to $2.8B in net product sales for 2026. - Pending addition of VYKAT XR from Soleno Therapeutics acquisition, expected to close in Q2 2026, strengthening commercial portfolio. - Overall, continued broad accumulation of patients and strong prescription growth across portfolio reflected in record quarterly net product sales exceeding $800 million. No explicit orderbook or pending orders numbers were provided.